These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35332508)

  • 1. Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation?
    Cai C; Zhang HF; Yang NB; Lu MQ
    Hepatol Int; 2022 Apr; 16(2):480-481. PubMed ID: 35332508
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B reactivation in patients on biologics: A perfect storm.
    Elston DM
    J Am Acad Dermatol; 2022 Jan; 86(1):37-38. PubMed ID: 33048666
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of acute hepatitis B and reactivation of hepatitis B.
    Jindal A; Kumar M; Sarin SK
    Liver Int; 2013 Feb; 33 Suppl 1():164-75. PubMed ID: 23286861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Jin ZC; Chen JJ; Luo B; Zhang WH; Teng GJ
    Hepatology; 2023 Jan; 77(1):E5-E6. PubMed ID: 35839297
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.
    Choi J
    Gut Liver; 2023 Mar; 17(2):179-180. PubMed ID: 36918269
    [No Abstract]   [Full Text] [Related]  

  • 6. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Perrillo RP; Gish R; Falck-Ytter YT
    Gastroenterology; 2015 Jan; 148(1):221-244.e3. PubMed ID: 25447852
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of serum Golgi protein 73 for screening chronic hepatitis B virus infection patients needing antiviral therapy in the community.
    Duan J; Wen X; Wang H; Chen W; Gao P; Yuan Q; Zheng H; Liu Y; Wu J; Wang J; Yao M; Lu F
    Chin Med J (Engl); 2022 Nov; 135(22):2741-2743. PubMed ID: 36574219
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current view on hepatitis B diagnosis and therapy].
    Husa P
    Vnitr Lek; 2021; 67(1):48-50. PubMed ID: 33752391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Reddy KR; Beavers KL; Hammond SP; Lim JK; Falck-Ytter YT;
    Gastroenterology; 2015 Jan; 148(1):215-9; quiz e16-7. PubMed ID: 25447850
    [No Abstract]   [Full Text] [Related]  

  • 10. Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?
    Lau G; Yu ML; Wong G; Thompson A
    Hepatol Int; 2022 Apr; 16(2):482-483. PubMed ID: 35229274
    [No Abstract]   [Full Text] [Related]  

  • 11. Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies.
    Inoue J; Nakamura T; Masamune A
    Viruses; 2019 May; 11(5):. PubMed ID: 31109119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B reactivation and timing for prophylaxis.
    Tuna N; Karabay O
    World J Gastroenterol; 2015 Feb; 21(7):2263-4. PubMed ID: 25717269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?
    Ekpanyapong S; Reddy KR
    Clin Liver Dis; 2020 Aug; 24(3):317-333. PubMed ID: 32620274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers.
    Liang LY; Wong VW; Wong GL; Yip TC
    Clin Mol Hepatol; 2023 Jan; 29(1):113-117. PubMed ID: 36314042
    [No Abstract]   [Full Text] [Related]  

  • 15. Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen-negative/antibody to hepatitis B core antigen-positive patients receiving chemotherapy for onco-hematologic malignancies.
    Marignani M; Marzano A
    J Clin Oncol; 2011 Mar; 29(8):e210; author reply e211. PubMed ID: 21220585
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression.
    Lazarevic I; Banko A; Miljanovic D; Cupic M
    Viruses; 2019 Aug; 11(9):. PubMed ID: 31450544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients].
    Yoon EL
    Korean J Gastroenterol; 2019 Nov; 74(5):258-266. PubMed ID: 31765554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Spaan M; Bruce M; Agarwal K; Carey I
    Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis for hepatitis B reactivation during and after chemotherapy: many questions, some answers.
    Rund D
    Leuk Lymphoma; 2016; 57(6):1249-50. PubMed ID: 26762891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.